- 53 LR
Cash and cash equivalents of CHF8.0 million (as of June30, 2021)
Net revenue CHF4.5 million (H1-2020: CHF7.8 million)
Net result for period of CHF-20.5 million (H1-2020: CHF-31.8 million)
Pratteln, Switzerland, October15, 2021 Santhera Pharmaceuticals (SIX: SANN) announces the Companys financial results for the first half-year ended June30, 2021, and provides an update on corporate progress.
- Already in April 2021, Santhera and ReveraGen announced new clinical data of 2.5-year treatment outcome with vamorolone in patients with Duchenne muscular dystrophy (DMD).
- Based on clinical trial results, including long-term safety data up to 30 months, vamorolone at doses up to 6mg/kg/day was generally well-tolerated.
- In June 2021, Santhera announced positive topline results from its long-term Phase 4 LEROS study with Raxone (idebenone) in the treatment of LHON.